Search Results for "Drug"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Drug. Results 381 to 390 of 594 total matches.
Neratinib (Nerlynx) for Metastatic HER2-Positive Breast Cancer (online only)
The Medical Letter on Drugs and Therapeutics • Nov 14, 2022 (Issue 1663)
infection, and upper respiratory
tract infection.
DRUG INTERACTIONS — Neratinib is metabolized primarily ...
The oral tyrosine kinase inhibitor neratinib (Nerlynx –
Puma Biotechnology) has been approved by the FDA
for use in combination with capecitabine (Xeloda, and
generics) for treatment of advanced or metastatic
human epidermal growth factor receptor 2 (HER2)-positive breast cancer in adults who received ≥2 prior
anti-HER2-based regimens for metastatic disease.
It was previously approved for use as monotherapy
for extended adjuvant treatment of adults with early-stage,
HER2-positive breast cancer following adjuvant
trastuzumab (Herceptin)-based therapy. HER2 is
overexpressed in...
In Brief: A Second Indication for Tucatinib (Tukysa) (online only)
The Medical Letter on Drugs and Therapeutics • Feb 20, 2023 (Issue 1670)
starting tucatinib and every 3 weeks during
treatment.
DRUG INTERACTIONS — Tucatinib is metabolized ...
The oral kinase inhibitor tucatinib (Tukysa – Seagen)
has received accelerated approval from the FDA for
use in combination with trastuzumab (Herceptin)
for treatment of adults with RAS wild-type human
epidermal growth factor receptor 2 (HER2)-positive
unresectable or metastatic colorectal cancer
that has progressed following treatment with
fluoropyrimidine-, oxaliplatin-, and irinotecan-based
chemotherapy regimens. Tucatinib was approved in
2020 for use in combination with trastuzumab and
capecitabine (Xeloda, and generics) for treatment
of adults with advanced unresectable or...
Med Lett Drugs Ther. 2023 Feb 20;65(1670):e37-8 doi:10.58347/tml.2023.1670g | Show Introduction Hide Introduction
Axatilimab (Niktimvo) for Chronic Graft-Versus-Host Disease (online only)
The Medical Letter on Drugs and Therapeutics • Nov 11, 2024 (Issue 1715)
drugs to distinguish reference
products from their biosimilars.
MECHANISM OF ACTION ― Axatilimab ...
Axatilimab-csfr (Niktimvo – Incyte), a colony
stimulating factor-1 receptor-blocking antibody, has
been approved by the FDA for intravenous treatment
of chronic graft-versus-host disease (cGVHD) after
failure of at least 2 lines of systemic therapy in patients
weighing ≥40 kg. Corticosteroids are generally the
first-line treatment for cGVHD. The oral kinase
inhibitors ibrutinib (Imbruvica), ruxolitinib (Jakafi),
and belumosudil (Rezurock) are also approved for
treatment of cGVHD. Extracorporeal photopheresis
has been used off-label.
Med Lett Drugs Ther. 2024 Nov 11;66(1715):e184-5 doi:10.58347/tml.2024.1715e | Show Introduction Hide Introduction
Vuity - Pilocarpine Ophthalmic Solution for Presbyopia
The Medical Letter on Drugs and Therapeutics • Feb 07, 2022 (Issue 1643)
Pilocarpine constricts the pupil, reducing available
light in low-light situations; while the drug is
active ...
The FDA has approved Vuity (Abbvie), a 1.25%
ophthalmic solution of the muscarinic receptor
agonist pilocarpine hydrochloride, for treatment of
presbyopia in adults. Pilocarpine 1%, 2%, and 4%
ophthalmic solutions (Isopto Carpine, and others)
have been available for years for treatment of
glaucoma, but local and systemic adverse effects
have limited their use.
In Brief: Fam-trastuzumab deruxtecan (Enhertu) for Breast Cancer (online only)
The Medical Letter on Drugs and Therapeutics • Apr 03, 2023 (Issue 1673)
;
such suffixes are added to biologic drugs to distinguish
reference products from their biosimilars.
e61 ...
Fam-trastuzumab deruxtecan-nxki (Enhertu – Daiichi
Sankyo/AstraZeneca), which received accelerated
approval by the FDA in 2019 for treatment of HER2-positive breast cancer based on its rate and duration
of response,1 has been granted regular approval for
treatment of adults with unresectable or metastatic
HER2-positive breast cancer who received a prior
anti-HER2-based regimen in the metastatic setting or
in the neoadjuvant or adjuvant setting and developed
recurrence during or within 6 months of completing
treatment.
Med Lett Drugs Ther. 2023 Apr 3;65(1673):e60-1 doi:10.58347/tml.2023.1673f | Show Introduction Hide Introduction
Erdafitinib (Balversa) for Urothelial Carcinoma (online only)
The Medical Letter on Drugs and Therapeutics • May 13, 2024 (Issue 1702)
and select FGFR
alterations. The drug should not be used in patients who have
not received prior PD-1 or PD ...
Erdafitinib (Balversa – Janssen), an oral kinase
inhibitor, has received full approval from the FDA
for treatment of locally advanced or metastatic
urothelial carcinoma in adults with susceptible
FGFR3 (fibroblast growth factor receptor) genetic
alterations who had disease progression on or after
at least one prior line of systemic therapy. It is not
recommended for use in patients who are eligible
for but have not received prior PD-1 (programmed
death receptor-1) or PD-L1 (programmed death-ligand
1) inhibitor therapy. Erdafitinib is the first
oral FGFR kinase inhibitor to be...
Med Lett Drugs Ther. 2024 May 13;66(1702):e83-4 doi:10.58347/tml.2024.1702g | Show Introduction Hide Introduction
Tebentafusp (Kimmtrak) for Uveal Melanoma (online only)
The Medical Letter on Drugs and Therapeutics • Jun 24, 2024 (Issue 1705)
with chemotherapy.3
In patients who received tebentafusp for a minimum
of 36 months, the drug extended median ...
The FDA has approved tebentafusp-tebn (Kimmtrak –
Immunocore), a first-in-class bispecific gp100
peptide-HLA-directed CD3 T-cell engager, for
treatment of HLA-A*02:01-positive unresectable or
metastatic uveal melanoma in adults.
Med Lett Drugs Ther. 2024 Jun 24;66(1705):e107-8 doi:10.58347/tml.2024.1705f | Show Introduction Hide Introduction
Tarlatamab (Imdelltra) for Small Cell Lung Cancer (online only)
The Medical Letter on Drugs and Therapeutics • Jul 08, 2024 (Issue 1706)
common.
Life-threatening neurotoxicity and cytokine release syndrome
can occur.
Drug Interactions ...
Tarlatamab-dlle (Imdelltra – Amgen), a first-in-class
bispecific delta-like ligand 3 (DLL3)-directed CD3
T-cell engager, has received accelerated approval
from the FDA for treatment of extensive-stage
small cell lung cancer (SCLC) in adults who had
disease progression on or after platinum-based
chemotherapy. It is the first bispecific DLL3-directed
CD3 T-cell engager to be approved in the US for this
indication. Most patients with SCLC have a response
to initial treatment, but progression generally
occurs within a few months and overall survival is
usually less than 8 months....
Med Lett Drugs Ther. 2024 Jul 8;66(1706):e113-4 doi:10.58347/tml.2024.1706c | Show Introduction Hide Introduction
Brella Sweat Control Patch for Primary Axillary Hyperhidrosis (online only)
The Medical Letter on Drugs and Therapeutics • Jul 22, 2024 (Issue 1707)
-acting anticholinergic drug
glycopyrronium, modestly reduces axillary sweat
production, but it can ...
Brella Sweat Control Patch (Candesant Biomedical),
a sodium-containing transdermal patch, has been
cleared by the FDA for in-office treatment of primary
axillary hyperhidrosis in adults. It is the first patch to
be approved in the US for this indication.
Med Lett Drugs Ther. 2024 Jul 22;66(1707):e125-6 doi:10.58347/tml.2024.1707i | Show Introduction Hide Introduction
Live Fecal Microbiota Oral Capsules (Vowst) for Prevention of CDI Recurrence
The Medical Letter on Drugs and Therapeutics • May 29, 2023 (Issue 1677)
. Med Lett Drugs Ther 2023; 65:35.
2. Treatment of Clostridioides difficile infection. Med Lett Drugs ...
The FDA has approved Vowst (Seres Therapeutics/Nestle HealthScience), an oral capsule containing live
fecal microbiota spores, for prevention of additional
recurrences of Clostridioides difficile infection (CDI)
in adults. Vowst is the first orally administered
microbiota-based treatment to be approved for
this indication. A rectally-administered live fecal
microbiota-based suspension (Rebyota) was
approved in 2022 for the same indication. Neither
product is approved for acute treatment of CDI.
Med Lett Drugs Ther. 2023 May 29;65(1677):81-2 doi:10.58347/tml.2023.1677a | Show Introduction Hide Introduction